Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding - 2Deadly heat worldwide prompts $300 million for climate health research at COP30
- 3Expert advice for new stargazers: How to begin your amateur astronomy journey
- 4NASA set to launch Artemis 2 moon mission today, the 1st crewed lunar flight since 1972
- 5Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- You finally got a doctor's appointment. Here's how to get the most out of it
- What to know about MIT professor Nuno Loureiro and the investigation into his shooting
- Israel’s 'Stonehenge’ not alone with near 30 similar sites, satellite imagery reveals
- A volcanic eruption may have catalyzed the plague's arrival in Europe, study suggests
- Cyber Monday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Israel strikes Iranian nuclear development facilities, Tehran vows retaliation
- New trailer for 'Bridgerton' Season 4 teases Benedict's love story: Watch it here
- 'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- Israel faces tough choices over haredi draft exemptions, legal expert warns
